Targets › ACTHR
1 program from 1 company in 1 trial: 1 Phase 3; Genitourinary; next expected readout Apr 2027.
G protein-coupled receptor for corticotropin/ACTH, primarily expressed in adrenal cortex where it plays a key role in the regulation of adrenocortical function. Upon activation, couples to G(s) protein, stimulating adenylate cyclase and activating the cAMP-dependent signaling pathway, the MAPK cascade as well as the PKA pathway, leading to steroidogenic factor 1/NR5A1-mediated transcriptional activation. (UniProt, Q01718)
Open in Phaseline: the race on ACTHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cerium Pharmaceuticals | SNP-ACTH (1-39) Gel ACTH analog | ACTHR | Phase 3 | Primary Membranous Nephropathy | Apr 2027 |
Primary Membranous Nephropathy (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.